AU629520B2 - A medicament - Google Patents
A medicament Download PDFInfo
- Publication number
- AU629520B2 AU629520B2 AU26677/88A AU2667788A AU629520B2 AU 629520 B2 AU629520 B2 AU 629520B2 AU 26677/88 A AU26677/88 A AU 26677/88A AU 2667788 A AU2667788 A AU 2667788A AU 629520 B2 AU629520 B2 AU 629520B2
- Authority
- AU
- Australia
- Prior art keywords
- medicament
- zinc oxide
- aspirin
- sodium bicarbonate
- ammonium citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
This invention relates tc, a medicament, to a method of preparing it and to a method of treating diseased mammals.
This invention provides a medicament comprising a mixture of ferrL ammonium citrate and zinc oxide. Preferably, the medicament of the invention also includes aspirin (acetylsalicylic acid), sodium bicarbonate and citric acid. It ,s found that the medicament works more quickly if these components are included. Optionally, chlorpropamide and/or Vitamin BI may be included for added efficacy.
The aspirin, sodium bicarbonate and citric acid components which are in the preferred form of the medicament of the invention are found in convenient proportions in the coimnercially available preparation "Alka-Seltzer" (trade mark) and this commercial preparation may be used in the meaicament of the invention.
The optional chlorpropamide component is also available commercially under the trade marks Diabinese and Promide prescribed for treatment of uncomplicated diabetes mellitus.
Vitamin Bi is commonly available commercially.
Q. The proportions of each component in the medicament of the 4. 20 invention may be varied to suit the subject being treated, as will be discussed below, and as will be readily apparent to one skilled in the art. Example 1, below, sets out the preferred 7 proportions for treatment of humans. These proportions can be I I U -3expressed as a percentage by weight, as follows: 7 8% aspirin, 41 42% sodium bicarbonate, 22 25% citric acid, 17 18% ferric ammonium citrate and 11 13% zinc oxide.
This invention also provides a method of preparing a medicament, comprising dissolving or suspending in water, or another suitable carrier, ferric ammonium citrate and zinc oxide, and, optionally, aspirin, sodium bicarbonate aud citric acid.
In addition, this invention provides a method of treating a diseased mammal, comprising administering to the diseased mammal a pharmaceutically effective amount of ferric ammonium citrate and zinc oxide ir, admixture, with the optional addition of aspirin, sodium bicarbonate, citric acid, chlorpropamid and/or Vitamin BI.
Tests which have beren carried out indicate that the medicament of the invention is capable of treating oie or more of the 4 4 following diseases: arthritis, bronchitis, diabetes, 20 arteriosclerosis, broken bones, Parkinson's disease, high blood i 4* cholesterol, cirrhosis of the liver, enlargement of the prostate gland. Often, more than one of these diseases may be treated simultaneously. It is believed that the medicament of S the invention may be capable of treating other diseases, perhaps even acquired immuno-deficiency syndrome but i^ir -4suitable tests have not yet been carried out. Similarly, the medicament of the invention may also neutralise radiation, even after a nuclear explosion.
It is thought that the medicament of the invention has a beneficial effect on mammalian cells, perhaps changing the ionisation of the atoms in the cells from positive (in which state the cell may be uncontrollable and vulnerable to disease) to negative (when the cell is under control and healthy).
Whether the above theory is accurate or not, it is certainly the case that the effect of the combination of ferric ammonium citrate and zinc oxide is quite different from expectations based on a knowledge of the individual components. It is apparent that the components work together in synergy to produce a quite unexpected result.
The invention will now be described in connection with examples thereof, which are not to be regarded as limiting on the scope of the invention.
t o EXAMPLE 1 The following were dissolved or suspended in 100 ml water: 20 324 mg aspirin, 1900 mg sodium bicarbonate and 1050 mg citric *9 acid (obtained as 1 tablet of "Alka-Seltzer" trade mark); 825 mg ferric ammonium citrate and 515 mg zinc oxide ALiv-S The resultant solution/suspension was suitable for ingestion as la draught, EXAMPLE 2 In this Example, the medicament comprised 1 tablet of "Alka-Seltzer" (trade mark), containing 324 mg aspirin, 1900 mg sodium bicarbonate and 1050 mg citric acid; 825 mg ferric ammonium citrate 515 mg zinc oxide one tablet of chiorpropamide (250 mg) and t~qo tablets of vitamin Bl.
EXAMPLE 3 The medicament of Example 2 was varied by providing an extra two tablets of aspirin of approximately 300 mg each. This combination is useful for cases of severe di(abetes. It is also useful to increase the amount of zinc oxide in such cases.
EXAMPLE 4 Tests have shown that the muedicaments described in Examples I to 3 may be administered once a day, or, in half the given quantities, twice a day. For children under 12 years of age, the daily dose should be half that of adults. For othe,-' mammals, the dose should be adjusted for body weight; experimentation will show the correct dose, as illustatLad by Example 7, below.
EXAMPLE The test subject was a male Caucasian aged 63 years at tho commencement of the test. The subject had suffered from mal~aria for many years and had cirrhosis of the liver. About ten years z~ before commencement of testing the subject hadi had a "bypass" -6operation to alleviate arteriosclerosis. The subject lost mobility and developed severe arthritis and gastritis as well as colon cancer. During surgical treatment for colon cancer, it was found that the subject was disbetic. The subject also suffered from bronchitis every winter and commenced to develop i an enlarged prostate.
The subject took small amounts of ferric ammonium citrate and zinc oxide in admixture each day, as well as 2 tablets of "Alka-Seltzer" two or three times a day, Vitamin B1 was taken 3 i 10 times a day and 1 tablet of aspirin daily. After 21 days, the diabetes disappeared.
The subject continued to take the above combination, but the quantity of ferric ammonium citrate and zinc oxide was gradually increased to 825 mg and 515 mg, respectively, per *day ("the optimum dose"). The subject noticed an increase in energy.
Zinc oxide was then omitted from the daily dose and copper oxide or sulphate was substituted. The diabetes returned. The diabetes disappeared again once the zinc oxide component was restored to the dose.
The subject continued to take the optimum dose and over time the arthritis symptoms were substantially alleviated. After the subject had been taking the dose for almost five years, S~t analysis showed low blood cholesterol, no arteriosclerosis and no cirrhosis of the liver. In addition, the subject no longer -7suffered from bronchitis and was not susceptible to influenza.
The subject's prostate problems disappeared after a programme of pelvic floor exercises. The subject enjoys a feeling of general well-being and vigour which is quite unusual, given the subject's age and medical background.
EXAMPLE 6 The subject was a female Caucasian of 70 years at the commencement of treatment. The subject had suffered a slight stroke shortly before and had Parkinson's disease, with the associated trembling symptoms.
After taking the medicament of Example 1 as well as Vitamin Bl once daily, there was a slow but definite improvement in the subject, so that after six months the subject's tremors were reduced by 50% and after one year, the symptoms were reduced by to EXAMPLE 7 A pair of fillies, one with a broken pelvis and the other with a broken hip, were dosed daily with a medicament comprising zinc oxide in admixture with ferric ammonium citrate, and S 20 vitamins. In addition, two spoons of sulphur were given to the fillies once a week. At first, relatively small amounts of o* zinc oxide and ferric ammonium citrate were administered, then -T the dose was increased daily until it reached a maximum of 5.15 S/o g zinc oxide and 8.25 g ferric ammonium citrate, per day, i.e., S ten times the quantity of these components in the medicament of -1"
.I
-8- Example 1. The treatment was successful; the fillies improved, the breaks healed and both fillies became energetic and could gallop actively.
It will be apparent to one skilled in the art that the proportions of the components of the medicament of this invention may be variable and are not limited to the precise amounts or percentages indicated herein. Moreover, the method of administration of the medicament may be variable; future tests may show that the medicament may be administered in suppository form, for example.
In addition, it is contemplated that the medicament of the invention may well be effective against diseases not referred to herein.
t
I,
I I i 1)1(
Claims (9)
1. A medicament comprising ferric ammonium citrate in admixture with zinc oxide and optionally including aspirin, sodium bicarbonate and citric acid.
2. A medicament as claimed in claim 1 wherein the medicament contains 7 8% aspirin, 41 42% sodium bicarbonate, 22 23% citric acid, 17 18% ferric ammonium citrate and 11 13% zinc oxide, by weight.
3. A medicament as claimed in claim 1 or 2, wherein the medicament also includes chlorpropamide.
4. A medicament as claimed in any one of claims 1 to 3, wherein the medicament also includes vitamin Bl.
A method of preparing a medicament as claimed in claim 1, comprising dissolving or suspending in water, or another suitable carrier, ferric ammonium citrate and zinc oxide and, Soptionally, aspirin, sodium bicarbonate and citric acid.
6. A method as claimed in claim 5, wherein 7 8% aspirin, 41 42% sodium bicarbonate, 22 23% citric acid, 17 18% ferric ammonium citrate and 11 13% zinc oxide, by weight, are dissolved or suspended in 100 ml water.
7. A method of treating a mammal, suffering from a disease chosen from the group consisting of arthritis, bronchitis, a diabetes, arteriosclerosis, broken bones, Parkinson's disease, S'.4 S* t I 31 1 I I I high blood cholesterol, cirrhosis of the liver, enlargement of the prostate gland comprising administering to the diseased mammal a pharmaceutically effective amount of ferric ammonium citrate in admixture with zinc oxide, with the optional addition of aspirin, sodium bicarbonate, citric acid, chlorpropamide and/or Vitamin Bl
8. A method as claimed in claim 7, wherein 7 8% of aspirin, 41 42% sodium bicarbonate, 22 23% citric acid, 17 18% ferric ammonium citrate and 11 13% zinc oxide, by weight, are administered to the diseased mamnal.
9. A medicament substantially as herein described with reference to any one of Examples 1 to 3. A method of Iaes en treating a diseased mammal as claimed in claim 7, substantially as herein described with reference to any one of Examples 4 to 7. to a. a 4 Dated this eleventh day of August, 1992 SPYROS CARANTINOS By his Patent Attorney KERRY MOORE CHRYSILIOU of CHRYSILIOU MOORE CHRYSILIOU II it -11- ABSTRACT This invention relates to a medicament comprising ferric ammonium citrate in admixture with zinc oxide and optionally including aspirin, sodium bicarbonate, citric acid, chlorpropamide and/or Vitamin B1, to a method of preparing it and to a method of treating a diseased mammal, comprising administering to the diseased mammal a pharmaceutically effective amount of the medicament. 4 6 I a 4 0 t f
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPI5803 | 1987-12-08 | ||
AUPI580387 | 1987-12-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2667788A AU2667788A (en) | 1989-06-08 |
AU629520B2 true AU629520B2 (en) | 1992-10-08 |
Family
ID=3772629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU26677/88A Ceased AU629520B2 (en) | 1987-12-08 | 1988-12-08 | A medicament |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU629520B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001030324A2 (en) * | 1999-10-27 | 2001-05-03 | Aufsess Joachim G | Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia |
-
1988
- 1988-12-08 AU AU26677/88A patent/AU629520B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2667788A (en) | 1989-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1243605A (en) | Antidiarrheal compositions and use thereof | |
JP3721196B2 (en) | Use of magnesium-based products for the treatment or prevention of neoplastic and autoimmune diseases | |
EP0150792B1 (en) | Drugs and the use of poorly soluble compounds of calcium and/or magnesium for the production of drugs | |
JPS6463522A (en) | Pharmaceutical composition for treating and preventing gallstone and gall deficient indigestion | |
GB2374008A (en) | Compositions including copper and their uses | |
US2761807A (en) | Glycocyamine and methylating agent in vivo creatine producing composition | |
JP3622985B2 (en) | How to increase magnesium absorption and prevent atherosclerosis | |
EP0372676A1 (en) | Therapeutic preparation and method | |
AU629520B2 (en) | A medicament | |
DE19910682A1 (en) | Fibrate based preparation for treating hyperlipoproteinemia additionally contains vitamin or related compound, e.g. cobalamin or folic acid, to prevent the side effect of hyperhomocysteinemia | |
US4591503A (en) | Composition for improved absorption of 2A cations and gold comprising yeast or Lactobacillus | |
EP0190851B1 (en) | Improved antiinflammatory composition | |
Mittleman et al. | Thyrocalcitonin activity in hypercalcemia produced by calcium salts, parathyroid hormone and vitamin D | |
US4650668A (en) | Composition for relieving toothache pain and other forms of intense pain | |
US3287220A (en) | Anti-asthmatic composition and methods | |
Allan et al. | Interaction between diuretics and indomethacin. | |
GB2194885A (en) | Pharmaceutical compositions containing vanadium | |
US5433954A (en) | Method and composition for treating psoriasis, seborrheic dermatitis and eczema | |
JPH01221316A (en) | Cerebral circulatory metabolism-improving agent | |
JPH0415766B2 (en) | ||
US5681593A (en) | Method and composition for treating psoriasis, seborrheic dermatitis and eczema | |
JPH0232020A (en) | Method and drug for suppressing manifestation of tolerance in morphine analgestic treatment | |
KR100631873B1 (en) | Alendronic Acid Formulations with Enhanced Bioavailability | |
US2085794A (en) | Urinary antiseptic | |
Wagner et al. | Treatment of intestinal helminths in Nigeria with triclofenol piperazine |